Back to resultsExpanded Access to Tipifarnib
Primary Purpose
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Tipifarnib
Sponsored by
About this trial
This is an expanded access trial for HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Eligibility Criteria
Inclusion/Exclusion Criteria:
Suffer from HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL)
Adult, ages 18+
Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Are ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology clinical or medically responsible individual
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04809233
Brief Title
Expanded Access to Tipifarnib
Study Type
Expanded Access
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kura Oncology, Inc.
4. Oversight
5. Study Description
Brief Summary
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
To request access, use Responsible Party contact information provided in this record.
Expanded access for tipifarnib is only available in the United States.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Tipifarnib
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion/Exclusion Criteria:
Diagnosed with HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL).
Adult, ages 18+.
Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kura Oncology Expanded Access
Phone
(858) 500-8800
Email
ExpandedAccess@kuraoncology.com
12. IPD Sharing Statement
Learn more about this trial
Expanded Access to Tipifarnib
We'll reach out to this number within 24 hrs